Evidence map›Paper›PMID 36302951›Full record

ArticleScientific reports2022

Expression of membrane Hsp90 is a molecular signature of T cell activation.

Scott A Scarneo, Aaron P Smith, Jacob Favret, Robert O'Connell, Joy Pickeral, Kelly W Yang, Guido Ferrari, David R Loiselle, Philip F Hughes, Manjusha M Kulkarni and 6 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Food preservative tBHQ modulates Th17/TCurrent research in toxicology · 2026
    Article
  5. Review
  6. Article
  7. Heat shock protein 90α reduces CD8Cell death discovery · 2024
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Scott A Scarneo *Department of Pharmacology and Cancer Biology, Duke University School of Medicine, 308 Research Drive, Durham, NC, 27710, USA.
Aaron P Smith *Department of Pharmacology and Cancer Biology, Duke University School of Medicine, 308 Research Drive, Durham, NC, 27710, USA.
Jacob FavretBolder BioPath INC., Boulder, CO, 80301, USA.
Robert O'ConnellBolder BioPath INC., Boulder, CO, 80301, USA.
Joy PickeralDepartment of Surgery, Duke University School of Medicine, Durham, NC, 27710, USA.
Kelly W YangDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, 308 Research Drive, Durham, NC, 27710, USA.
Guido FerrariDepartment of Surgery, Duke University School of Medicine, Durham, NC, 27710, USA.
David R LoiselleDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, 308 Research Drive, Durham, NC, 27710, USA.
Philip F HughesDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, 308 Research Drive, Durham, NC, 27710, USA.
Manjusha M KulkarniDepartment of Microbiology, Ohio State University, Columbus, OH, 43210, USA.
Madhusudhana GargeshaBioInVision, Inc., Mayfield, OH, 44143, USA.
Bryan ScottBioInVision, Inc., Mayfield, OH, 44143, USA.
Debashish RoyBioInVision, Inc., Mayfield, OH, 44143, USA.
Barton F HaynesDepartment of Medicine, Duke University School of Medicine, Durham, NC, 27710, USA.
Jesse J KwiekDepartment of Microbiology, Ohio State University, Columbus, OH, 43210, USA.
Timothy A J HaysteadDepartment of Pharmacology and Cancer Biology, Duke University School of Medicine, 308 Research Drive, Durham, NC, 27710, USA. timothy.haystead@duke.edu.
Duke University · USBioInVision (United States) · USBolder Biotechnology, Inc. · USThe Ohio State University · US

Funding

Pharmacological Sciences Training ProgramT32GM007105 · NIGMS · DUKE UNIVERSITY · PI KUHN, CYNTHIA M · 1985 to 2019
$9.0M
Discovery and development of broad spectrum anti-flaviviral drugsR01AI089526 · NIAID · DUKE UNIVERSITY · PI ENGEL, DANIEL A, GARCIA-BLANCO, MARIANO A. · 2010 to 2014
$4.1M
DOD Peer Reviewed Cancer Research Program W81XWH-15-1-0072NIAID NIH HHS R01 AI089526NIGMS NIH HHS 5T32GM007105-44NIGMS NIH HHS T32 GM007105
6 · The paper itself

Abstract

Heat shock protein 90 (Hsp90) maintains cellular proteostasis during stress and has been under investigation as a therapeutic target in cancer for over two decades. We and others have identified a membrane expressed form of Hsp90 (mHsp90) that previously appeared to be restricted to rapidly proliferating cells exhibiting a metastatic phenotype. Here, we used HS-131, a fluor-tethered mHsp90 inhibitor, to quantify the effect of T cell activation on the expression of mHsp90 in human and mouse T cells. In cell-based assays, stimulation of human T cells induced a 20-fold increase in mHsp90 expression at the plasma membrane, suggesting trafficking of mHsp90 is regulated by TCR and inflammatory mediated signaling. Following injection of HS-131 in mouse models of human rheumatoid arthritis and inflammatory bowel disease, we detected localization of the probe at sites of active disease, consistent with immune cell invasion. Moreover, despite rapid hepatobiliary clearance, HS-131 demonstrated efficacy in reducing the mean clinical score in the CIA arthritis model. Our results suggest mHsp90 expression on T cells is a molecular marker of T cell activation and potentially a therapeutic target for chronic diseases such as rheumatoid arthritis.

Indexed as

Arthritis, RheumatoidLymphocyte ActivationAnimalsDisease Models, AnimalHSP90 Heat-Shock ProteinsHumansMiceT-LymphocytesHSP90 Heat-Shock Proteins

Identifiers

PMID36302951
PMCPMC9613876
OpenAlexW4307405581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.